An Open-Label, Long-Term Study to Assess the Safety and Efficacy of YM178 in Symptomatic Overactive Bladder Patients.
Phase of Trial: Phase III
Latest Information Update: 16 Jul 2013
At a glance
- Drugs Mirabegron (Primary)
- Indications Overactive bladder
- Focus Adverse reactions; Registrational; Therapeutic Use
- 08 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Jun 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
- 01 Apr 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.